Research Pulse — 2026-09-29 | Brown Biotech

# Research Pulse — 2026-09-29
_Generated 2026-09-29 07:30 KST · AI × Bioresearch Daily synthesis_

Brown Biotech daily research pulse — multi-front synthesis across CRISPR /
gene editing, AI drug discovery, protein AI, single-cell foundation models,
FDA/regulatory, and spatial transcriptomics. Sources: company filings,
peer-reviewed journals, FDA guidance, conference disclosures.

---

### Post 1: 오늘의 전체 흐름

🧬 **AI × Bioresearch Daily — 9월 29일 (화요일) · Embedding(안착) Day**

9/29(안착) → 9/28(제도화) → 9/27(성숙) → 9/26(번역) → 9/25(시너지) → 9/24(확장) → 9/23(진전) → 9/22(집적화). Institutionalizing(9/28)된 기술들이 **제도화된 프레임워크 안에서 실제 산업·임상에 안착(Embedding)하며, FDA Gene Therapy 플랫폼 규제 제도化成 → Kresladi(2026년 3월 승인) 구체적 제품 승인으로 이행 ·AI drug discovery가 algorithmic foundations에서 clinical translation واقع화 →precision oncology에서 구체적 TNTK inhibitor Phase IIa烬果로 이행 ·단백질 구조 AI가 quality assessment framework에서 practical application واقع화로 이행 ·nanomaterial-mediated CRISPR delivery가 제도화된 전달 체계로 안착 ·spatial omics가 atlas 구축 단계에서 clinical trial implementation 단계로 이행 등 기술이 제도적 기반 위에서 실제 제품·치료·표준화로 안착하는 Embedding(안착) 단계로 이전하며, 기술이 framework adoption에서 practical deployment로 이행하는 날** — Kresladi(Leukocyte Adhesion Deficiency-I gene therapy) FDA 승인 2026년 3월 구체적 제품화로 FDA 플랫폼 규제의制度化→실제 제품 이행 확인(Sheikh Annals of Medicine and Surgery 2026), nanomaterial-mediated CRISPR/Cas delivery — lipid nanoparticles·polymeric·inorganic·EV-derived systems comprehensive review + repeated targeted applications 가능성 확인(Wang Frontiers Bioengineering 2026), Yoo precision oncology AI — TNIK inhibitor Phase IIa efficacy + AI-driven drug discovery의 oncology 실제 적용 확인(BJC Reports 2026), Yin AlphaFold comprehensive review — AF→AF2→AF3 architectural evolution + practical applications in drug discovery·enzyme engineering·disease research (Frontiers Molecular Biosciences 2026), DenAdel single-cell FM scaling law — 22.2M cells 400 models 6,400 experiments + scaling law 부재确认 (Nature Methods 2026), Li IBD spatial atlas — CosMx vs Xenium 2개 플랫폼 비교 benchmark + multi-center operational feasibility (Nature Communications 2026)가 동시에 진행된다.

Embedding은 Institutionalizing의 다음 단계다. 오늘 6개 전선은 제도화된 기술들이 **구체적 제품·치료·적용 사례와 표준화로 안착하며, framework adoption에서 practical deployment로 이행하는 날**이다.

*출처: [Sheikh Kresladi FDA Approval Annals of Medicine and Surgery 2026](https://consensus.app/papers/details/f2f27f7392e05d9693a11da0cb87b29d/), [Wang Nanomaterial CRISPR Frontiers Bioengineering 2026](https://consensus.app/papers/details/f43692af0ccb54b684ef6714b3de8d82/), [Yoo Precision Oncology AI BJC Reports 2026](https://consensus.app/papers/details/3061bab99a9351b297c698ef342d7f34/), [Yin AlphaFold Comprehensive Frontiers Molecular Biosciences 2026](https://consensus.app/papers/details/880e72fce35255c4887811c76849c03a/), [DenAdel Single-Cell FM Scaling Law Nature Methods 2026](https://consensus.app/papers/details/f0f6bddc16985563ad8478918950e0f4/), [Li IBD Spatial Atlas Nature Communications 2026](https://consensus.app/papers/details/02da1d5a4d605f7bb65ef940bb94ed56/)*

*#EmbeddingDay #Sheikh #Kresladi #LAD #FDAApproval2026 #GeneTherapy #AnnalsOfMedicine #Wang #Nanomaterial #CRISPR #LipidNanoparticle #ExtracellularVesicle #FrontiersBioengineering #Yoo #PrecisionOncology #TNIKInhibitor #BJCReports #Yin #AlphaFold #FrontiersMolecularBiosciences #DenAdel #NatureMethods #SingleCell #FoundationModel #ScalingLaw #Li #IBD #Crohn #UlcerativeColitis #CosMx #Xenium #NatureCommunications #Embedding #Institutionalizing #ClinicalDeployment #ProductLaunch #BiomedicalAI #DailyReport*

---

### Post 2: CRISPR & Gene Editing — Kresladi FDA 승인 × Nanomaterial Delivery安착: Embedding

🪄 **[CRISPR/Gene Editing] Sheikh et al.로 Kresladi(marnetegra-gene autotemcel) FDA 승인 2026년 3월 26일 — Leukocyte Adhesion Deficiency-I (LAD-I) gene therapy 구체적 제품화(Sheikh Annals of Medicine and Surgery 2026) + Wang et al.로 nanomaterial-mediated CRISPR/Cas delivery comprehensive review — lipid nanoparticles·polymeric·inorganic·EV-derived systems + repeated targeted applications + standardization (Frontiers Bioengineering 2026) + Zhao et al.로 DNA/RNA editing therapy current status — delivery efficiency·tissue specificity·genotoxicity·immunogenicity 체계적 분석(Molecular Biomedicine 2026): CRISPR Embedding(안착) 동시 확인**

CRISPR gene therapy의**구체적 제품 승인 + 전달 기술의 산업 표준화(Embedding)**가 출처에서 동시에 확인된다[1][2][3].

**Kresladi FDA Approval March 2026: LAD-I Gene Therapy 구체적 제품화[1]**
M. Sheikh et al.(Annals of Medicine and Surgery 2026)의 연구는 Kresladi(marnetegra-gene autotemcel) FDA 승인(2026년 3월 26일)을 분석한다[1]. **Leukocyte Adhesion Deficiency-I(LAD-I)**: ITGB2 유전자 돌연변이로 인한 희귀 자가면역 결합면역부전. 2세 이전 75% 사망률, 중등도 질병 Childhood 병력 40세 50% 사망률. **기존 치료의 한계**: 항생제·호중구 수혈·조혈줄기세포 이식이식의 문제점(공여자 문제, graft-versus-host disease). **Kresladi 승인**: HLA 일치 형제 기증자 없는 LAD-I 소아 환자 치료용 유전자 치료제. **작용 기전**: 환자自身の 조혈줄기세포를 유전자 편집하여 ITGB2 발현 회복. **2026년 3월 26일 승인**: FDA가 구체적 제품으로 승인한 基因治療. 핵심: Kresladi FDA 승인(2026년 3월)으로 CRISPR gene therapy가 구체적 제품으로安착 — FDA 플랫폼 규제制度化→실제 제품 이행.

**Nanomaterial-Mediated CRISPR/Cas Delivery: 산업 표준 전달 체계 Comprehensive Review[2]**
Bingning Wang et al.(Frontiers in Bioengineering and Biotechnology 2026)의 review는 CRISPR/Cas 전달을 위한 나노소재 종합 분석한다[2]. **핵심 성과 1 — Lipid nanoparticles(LNPs)**: nucleic acids와 CRISPR/Cas systems의 전달에서 가장 진보된 성능 확인. **핵심 성과 2 — Polymeric nanoparticles**: repeated targeted applications에 진보. **핵심 성과 3 — Inorganic nanoparticles**: gold, silica nanostructures의 특성 분석. **핵심 성과 4 — Engineered extracellular vesicles(EVs)**: 세포외소포체 유래 전달체. **핵심 성과 5 — Design factors**: surface ligands, charge modification, PEGylation, stimulus-responsive behaviors. **핵심 성과 6 — Repeated applications 가능성**: hybrid and responsive systems로 spatial and temporal control 가능. **핵심 성과 7 — Standardized manufacturing 필요성**: 임상 안전성·신뢰성 확보를 위한 표준화 제조 필요. 핵심: nanomaterial-mediated CRISPR 전달 체계의 산업 표준화 — repeated targeted applications 가능성으로安착.

**DNA/RNA Editing Therapy: Delivery Efficiency·Tissue Specificity 체계적 분석[3]**
Rui Zhao et al.(Molecular Biomedicine 2026)의 review는 DNA/RNA editing tools의 치료 적용 현황과 과제를 종합한다[3]. **핵심 성과 1 — Delivery efficiency가 결정적**: in vivo therapeutic applications의 핵심 병목. **핵심 성과 2 — Tissue specificity 문제**: programmable delivery systems로 해결 가능성. **핵심 성과 3 — Genotoxicity·immunogenicity tracking**: safety assessment 확대. **핵심 성과 4 — Permanent( DNA editing) + reversible(RNA editing) 전략**: cargo-writing capacity와 low integration risk. **핵심 성과 5 — Programmable delivery systems**: hard-to-transfect tissues와 complex diseases로 확장 가능성. 핵심: DNA/RNA editing therapy의 전달 기술 체계적 분석 — CRISPR Embedding Consolidating.

**9월 28일 Institutionalizing(Luo HMGN1+VP64 base editing + Cho biocontainment) vs 오늘의 차별점**: 9/28이 Luo Advanced Science으로 **PAM-flexible base editing 표준화**를, Cho Nucleic Acids Research으로 **biocontainment NIH criterion**을 제시했다면, 오늘은 **Sheikh Annals**으로 **Kresladi FDA 승인(2026년 3월)이라는 구체적 제품**을(制度化→실제 제품 이행), **Wang Frontiers Bioengineering**으로 **nanomaterial delivery의 산업 표준화 체계**를(전달 기술安착), **Zhao Molecular Biomedicine**으로 **DNA/RNA editing therapy의 전달 기술 체계적 분석**을(치료 적용 확대) 동시에 제시한다. Institutionalizing(9/28) → 제품 승인 + 산업 표준安착 Embedding(9/29).

실무 함의: 유전자 치료 개발팀에서 Kresladi의 승인 사례를 분석하여 플랫폼 규제 기반 제품 개발 전략을 수립해야 한다.

*출처: [Sheikh Kresladi LAD-I FDA Approval Annals of Medicine and Surgery 2026](https://consensus.app/papers/details/f2f27f7392e05d9693a11da0cb87b29d/), [Wang Nanomaterial CRISPR Delivery Frontiers Bioengineering 2026](https://consensus.app/papers/details/f43692af0ccb54b684ef6714b3de8d82/), [Zhao DNA RNA Editing Therapy Molecular Biomedicine 2026](https://consensus.app/papers/details/ab669ea6603759258fd73951324f50a5/)*

*#CRISPR #GeneEditing #Sheikh #Kresladi #LADI #FDAApproval2026 #AnnalsOfMedicine #ITGB2 #HematopoieticStemCell #Wang #Nanomaterial #CRISPRDelivery #LipidNanoparticle #Polymeric #ExtracellularVesicle #FrontiersBioengineering #RepeatedApplication #Zhao #MolecularBiomedicine #DNAEditing #RNAEditing #DeliveryEfficiency #TissueSpecificity #Genotoxicity #Immunogenicity #EmbeddingDay #ProductLaunch #PlatformRegulation #GeneTherapy #Standardization #BiomedicalAI #DailyReport*

---

### Post 3: AI 신약 — Precision Oncology Phase IIa Efficacy + AI Oncology 실제 적용安착: Embedding

💊 **[AI 신약] Yoo et al.로 precision oncology AI — TNIK inhibitor Phase IIa efficacy烬果 + idiopathic pulmonary fibrosis case + AI-driven drug discovery oncology 적용确认(BJC Reports 2026) + Mao et al.로 AI drug discovery Phase IIa efficacy + Phase I safety 정지 + 0건 완전 AI 마케팅 승인 현실(Frontiers in Pharmacology 2026) + Cai et al.로 preclinical AI pipeline 종합 + multimodal AI·digital twins·closed-loop automation 미래(Pharmaceuticals 2026): AI Drug Discovery Embedding(안착) 동시 확인**

AI-Driven Drug Discovery의**oncology 실제 적용 + 임상 데이터현주소(Embedding)**가 출처에서 동시에 확인된다[4][5].

**Precision Oncology AI: TNIK Inhibitor Phase IIa Efficacy + Oncology 적용確認[4]**
Wonbeak Yoo et al.(BJC Reports 2026)의 perspective는 AI-driven drug discovery의 precision oncology 적용을 분석한다[4]. **핵심 성과 1 — TNIK inhibitor Phase IIa efficacy**: AI로 설계된 TNIK inhibitor가 idiopathic pulmonary fibrosis 환자에서 Phase IIa trial에서 efficacy 확인. **핵심 성과 2 — Safety·tolerability·pharmacodynamic target engagement 확인**: functional decline 감소 경향 확인. **핵심 성과 3 — AI-derived molecules가 human testing 진입 가능성 입증**: broader validation·mechanistic understanding·regulatory alignment 필요. **핵심 성과 4 — Oncology 적용 전략**: tumor heterogeneity·clonal evolution·therapeutic resistance 극복을 위한 adaptive·data-informed drug discovery 전략. **핵심 성과 5 — Multi-omics data integration·federated model validation·adaptive trial design**: precision oncology를 위한 practical strategies. 핵심: TNIK inhibitor Phase IIa efficacy로 AI-driven drug discovery가 oncology實際 적용 가능성 입증 — AI drug discovery Embedding Consolidating.

**AI Drug Discovery 임상 현주소: Phase IIa Efficacy + Phase I Safety 정지 + 0건 완전 승인[5]**
Zihan Mao et al.(Frontiers in Pharmacology 2026)의 review는 AI drug discovery의 임상 번역 현황을 종합한다[5]. **핵심 성과 1 — Phase IIa efficacy候补**: AI로 발견/설계된候补 중 Phase IIa에서 encouraging efficacy 보인 첫 성과. **핵심 성과 2 — Phase I safety候补**: AI候补 중 Phase I에서 safety signals로 정지된候补 — AI의 early detection 한계 확인. **핵심 성과 3 — 0건 완전 AI 마케팅 승인**: 완전 AI 발견/설계 약물의 마케팅 승인은 아직 없음. **핵심 성과 4 — AI 독성 earlier 단계 detection 가능하나 완전히 elimination은 불가**: biological complexity·patchy data·ML+pharmaceutics 인력 부족. **핵심 성과 5 — Multimodal AI·explainable AI 필요성**: transparency·regulatory confidence를 위한 필수 조건. 핵심: AI候补 첫 임상 데이터 현실 — efficacy + safety 정지 동시 존재 — AI drug discovery Embedding Consolidating.

**9월 28일 Institutionalizing(Lin pharma AI 2026 deals + Huynh AI agent pipeline) vs 오늘의差別점**: 9/28이 Lin GEN Biotechnology으로 **2026 pharma AI deal flurry**를, Huynh Drug Discovery Today으로 **AI agent pipeline 통합**을 제시했다면, 오늘은 **Yoo BJC Reports**으로 **TNIK inhibitor Phase IIa efficacy现实 + precision oncology 실제 적용**을(AI oncology安착), **Mao Frontiers Pharmacology**으로 **Phase IIa efficacy + Phase I safety 정지 + 0건 완전 승인 현실**을(현주소) 동시에 제시한다. Institutionalizing(9/28) → oncology 실제 적용 + 임상 현주소 Embedding(9/29).

실무 함의: AI drug discovery 팀에서 Yoo et al.의 TNIK inhibitor Phase IIa 결과를 참조하여 oncology 적용 전략을 수립해야 한다.

*출처: [Yoo Precision Oncology AI BJC Reports 2026](https://consensus.app/papers/details/3061bab99a9351b297c698ef342d7f34/), [Mao AI Drug Discovery Clinical Translation Frontiers in Pharmacology 2026](https://consensus.app/papers/details/ca5321af0bb656e095b6108766231764/), [Cai Preclinical AI Pipeline Pharmaceuticals 2026](https://consensus.app/papers/details/9db7efc33cb250c4b08b448e73fcdd17/)*

*#AI #DrugDiscovery #Yoo #BJCReports #PrecisionOncology #TNIKInhibitor #PhaseIIa #Efficacy #IdiopathicPulmonaryFibrosis #Mao #FrontiersinPharmacology #PhaseI #Safety #ZeroAIApproval #ClinicalTranslation #Cai #Pharmaceuticals #Preclinical #MultimodalAI #DigitalTwins #ClosedLoop #EmbeddingDay #OncologyApplication #ClinicalData #RealWorldEvidence #BiomedicalAI #DailyReport*

---

### Post 4: 단백질 AI — AlphaFold Practical Applications安착 + Comprehensive Review: Embedding

🔬 **[단백질 AI] Yin et al.로 AlphaFold practical applications comprehensive review — AF→AF2→AF3 architectural evolution + drug discovery·enzyme engineering·disease research 적용 + current challenges·future directions (Frontiers Molecular Biosciences 2026) + Feldman et al.로 AlphaFold3 adversarial mutations — 40% invariance + template memorization 문제 확인(Computational Biotechnology 2026) + DenAdel et al.로 single-cell FM plateau — scaling law 부재确认 + dataset size/diversity plateau 확인(Nature Methods 2026): 단백질 AI Embedding(안착) 동시 확인**

단백질 AI의**실용적 적용 안착 + comprehensive review 체계화(Embedding)**가 출처에서 동시에 확인된다[6][7].

**AlphaFold Practical Applications Comprehensive Review: Drug Discovery·Enzyme Engineering·Disease Research[6]**
Tianxiang Yin et al.(Frontiers in Molecular Biosciences 2026)의 review는 AlphaFold의 실용적 적용을 종합한다[6]. **핵심 성과 1 — AF→AF2→AF3 architectural evolution**: DNN → Evoformer → Pairformer 아키텍처 진화. **핵심 성과 2 — AlphaFold3의 확장**: protein-ligand·protein-nucleic acid·protein-protein complexes 예측 가능. **핵심 성과 3 — Drug discovery applications**: structure-based drug discovery 가속화. **핵심 성과 4 — Enzyme engineering applications**: 효소 설계 최적화. **핵심 성과 5 — Disease research applications**: 질병 기전 연구 적용. **핵심 성과 6 — ESMFold 속도·확장성**: single-sequence approaches로 속도 향상. **핵심 성과 7 — Current challenges**: protein dynamics·multiple conformational states 예측 한계. 핵심: AlphaFold practical applications의 comprehensive review — drug discovery·enzyme engineering·disease research 적용体系化 — 단백질 AI Embedding Consolidating.

**AlphaFold3 Adversarial Mutations: Template Memorization問題確認[7]**
J. Feldman et al.(Computational and Structural Biotechnology Journal 2026)의 연구는 AlphaFold3의 adversarial evaluation 결과를 제시한다[7]. **핵심 성과 1 — 40% invariance**: 점변이나 deletion에도 예측 구조 불변. **핵심 성과 2 — Template memorization 문제**: AlphaFold가 일반화된 생물물리학보다 template-based pattern matching에 의존 가능성. **핵심 성과 3 — Confidence metric unreliable**: 35% only accurate. **핵심 성과 4 — ESMFold 더 나은 sensitivity**: 완전히的不是完美. **핵심 성과 5 — Mutation-effect interpretation·confidence-guided model selection·sequence optimization workflows에 영향**. 핵심: AlphaFold template memorization 문제 체계적 분석 — 단백질 AI의 한계 인식 Embedding Consolidating.

**9월 28일 Institutionalizing(Sarti AF quality arity map + Lin AF oligomeric + Chakraborty Nobel) vs 오늘의差别점**: 9/28이 Sarti Bioinformatics Advances으로 **AF quality arity map 표준 프레임워크**를, Lin Protein Science으로 **oligomeric state prediction 정확도边界**를, Chakraborty Frontiers AI으로 **AlphaFold3 Nobel impact**를 제시했다면, 오늘은 **Yin Frontiers Molecular Biosciences**으로 **AlphaFold drug discovery·enzyme engineering·disease research practical applications comprehensive review**를(실용적 적용体系化), **Feldman Computational Biotechnology**으로 **AlphaFold template memorization 문제**를(한계 인식) 동시에 제시한다. Institutionalizing(9/28) → practical applications体系化 + 한계 인식 Embedding(9/29).

실무 함의: 약리활성 연구팀에서 Yin et al.의 AlphaFold practical applications review를 참조하여 구조 기반 약물 발견 전략을 수립해야 한다.

*출처: [Yin AlphaFold Practical Applications Frontiers Molecular Biosciences 2026](https://consensus.app/papers/details/880e72fce35255c4887811c76849c03a/), [Feldman AlphaFold3 Adversarial Mutations Computational Biotechnology 2026](https://consensus.app/papers/details/68f35194db525fb68a7bc8c10546001b/), [DenAdel Single-Cell FM Scaling Law Nature Methods 2026](https://consensus.app/papers/details/f0f6bddc16985563ad8478918950e0f4/)*

*#ProteinAI #AlphaFold #Yin #FrontiersMolecularBiosciences #ArchitecturalEvolution #DrugDiscovery #EnzymeEngineering #DiseaseResearch #Feldman #ComputationalBiotechnology #AdversarialMutation #Invariance #TemplateMemorization #ESMFold #DenAdel #NatureMethods #SingleCell #FoundationModel #ScalingLaw #Plateau #EmbeddingDay #PracticalApplication #ComprehensiveReview #Limitations #BiomedicalAI #DailyReport*

---

### Post 5: Single-Cell Multi-Omics Foundation Model — Scaling Law 부재 × Multi-Modal Integration安착: Embedding

🬬 **[Single-Cell Multi-Omics Foundation Model] DenAdel et al.로 single-cell FM pre-training dataset scaling — 22.2M cells 400 models 6,400 experiments + scaling law 부재确认 + dataset size plateau 확인(Nature Methods 2026) + Ji et al.로 CAPTAIN multimodal FM — scRNA + protein 382종 동시 측정 + cross-modality dependencies learning(Nature Communications 2026) + Wang et al.로 CellVQ 68M cells + SCD module interpretability (Nature Communications 2026): foundation model Embedding(안착) 동시 확인**

Single-Cell Foundation Model의**scaling law 부재確認 + multimodal integration 실용화(Embedding)**가 출처에서 동시에 확인된다[8][9][10].

**Single-Cell FM Scaling Law 부재: 22.2M Cells 400 Models Plateau 확인[8]**
Alan DenAdel et al.(Nature Methods 2026)의 연구는 single-cell foundation model의 pre-training dataset size와 diversity의 역할을 분석한다[8]. **핵심 성과 1 — 22.2 million cells corpus**: 대규모 학습 데이터. **핵심 성과 2 — 400 models training**: 다양한 모델 아키텍처 실험. **핵심 성과 3 — 6,400 experiments**: 포괄적 평가. **핵심 성과 4 — Scaling law 부재確認**: current methods가 현재 training corpora의 일부 크기에서 성능 plateau 도달. **핵심 성과 5 — Dataset size보다 balancing 중요**: model capacity·dataset size·computational resources의 균형이 indiscriminate 증가보다 중요. **핵심 성과 6 — No clear data scaling laws**: large language models와 달리 single-cell FM에서는 scaling law 관찰되지 않음. 핵심: Single-cell FM의 scaling law 부재 확인 — 데이터 크기보다 균형이 중요 — foundation model Embedding Consolidating.

**CAPTAIN Multimodal Foundation Model: scRNA + Protein 382종 동시 측정[9]**
Boya Ji et al.(Nature Communications 2026)의 연구는 CAPTAIN multimodal foundation model을 제시한다[9]. **핵심 성과 1 — 4 million+ single cells**: 대규모 multimodal 데이터. **핵심 성과 2 — 382 surface proteins 동시 측정**: transcriptomes + proteins 통합. **핵심 성과 3 — Cross-modality dependencies learning**: modality 간 의존성 학습. **핵심 성과 4 — Unified multimodal representations**: 세포 상태의 통합적 표현. **핵심 성과 5 — Protein imputation·expansion·cell type annotation·batch harmonization**: downstream tasks에서 superior performance. **핵심 성과 6 — COVID-19 severity 관련 immune interaction patterns**: novel biology 발견. 핵심: CAPTAIN multimodal FM으로 scRNA + protein 통합 representation learning 실현 — foundation model Embedding Consolidating.

**CellVQ Interpretable Foundation Model: 68M Cells + SCD Module[10]**
Jue Wang et al.(Nature Communications 2026)의 연구는 CellVQ foundation model을 제시한다[10]. **핵심 성과 1 — 68 million cells**: 대규모 학습 데이터. **핵심 성과 2 — 500 million parameters**: 대규모 모델. **핵심 성과 3 — Single-Cell Discretization(SCD) module**: 세포 Embedding을 "cell code"로 변환. **핵심 성과 4 — Interpretability 확보**: 고차원·희소 단일세포 데이터의 해석 가능성. **핵심 성과 5 — CellVQ-Graph**: multimodal knowledge graph tool. **핵심 성과 6 — All downstream tasks에서 strong baselines 상회**. 핵심: CellVQ로 interpretable foundation model 실현 — foundation model Embedding Consolidating.

**9월 28일 Institutionalizing(DenAdel FM plateau + Bahrami compositional FM) vs 오늘의差别점**: 9/28이 DenAdel Nature Methods으로 **FM scaling law plateau 확인**을, Bahrami Cell Systems으로 **compositional FM**을 제시했다면, 오늘은 같은 DenAdel paper에서 **400 models 6,400 experiments의 구체적 실험 규모 + scaling law 부재 mechanis**를(embedding — plateau 현상 이해深化), **Ji Nature Communications CAPTAIN**으로 **scRNA + 382 protein multimodal 통합**을(multi-modal Embedding), **Wang Nature Communications CellVQ**으로 **SCD module interpretability**를(interpretability Embedding) 동시에 제시한다. Institutionalizing(9/28) → scaling law plateau mechanis + multimodal + interpretability Embedding(9/29).

실무 함의: 단일세포 연구팀에서 DenAdel et al.의 scaling law 분석을 참조하여 foundation model training 전략을 수립해야 한다.

*출처: [DenAdel Single-Cell FM Scaling Law Nature Methods 2026](https://consensus.app/papers/details/f0f6bddc16985563ad8478918950e0f4/), [Ji CAPTAIN Multimodal Foundation Nature Communications 2026](https://consensus.app/papers/details/40361e55d4815c1dae3d5f6a95d4468a/), [Wang CellVQ Interpretable Foundation Nature Communications 2026](https://consensus.app/papers/details/89622623baa35922aaca1c5b88e6ce8b/)*

*#SingleCell #FoundationModel #DenAdel #NatureMethods #ScalingLaw #Plateau #22MillionCells #400Models #6400Experiments #Ji #CAPTAIN #Multimodal #NatureCommunications #382Proteins #CrossModality #Wang #CellVQ #SCD #Interpretability #CellCode #EmbeddingDay #Balancing #DataScaling #MultimodalIntegration #Interpretability #BiomedicalAI #DailyReport*

---

### Post 6: FDA/규제 — Kresladi 2026년 3월 승인 × 플랫폼 규제制度化→제품 이행: Embedding

📋 **[FDA/규제] Sheikh et al.로 Kresladi(marnetegra-gene autotemcel) FDA 승인 2026년 3월 26일 — Leukocyte Adhesion Deficiency-I gene therapy 구체적 제품화(Sheikh Annals of Medicine and Surgery 2026) + Oo et al.로 FDA Gene Therapy 38개 승인 comprehensive review — platform-aligned risk-based + plausible mechanism + CMC flexibility + AI/ML analytics 체계화(J Clinical Pharmacology 2026) + Shahzad et al.로 FDA CGT 38개 승인 assessment — 86.8% orphan·92.1% expedited pathway·44.7% surrogate endpoints(Clinical Pharmacology 2026): FDA/규제 Embedding(안착) 동시 확인**

FDA/규제의**구체적 제품 승인 + 플랫폼 규제 체계의 제품 이행(Embedding)**이 출처에서 동시에 확인된다[1][11][12].

**Kresladi FDA Approval March 2026: LAD-I Gene Therapy 구체적 제품화[1]**
M. Sheikh et al.(Annals of Medicine and Surgery 2026)의 연구는 Kresladi(marnetegra-gene autotemcel) FDA 승인(2026년 3월 26일)을 분석한다[1]. **Leukocyte Adhesion Deficiency-I(LAD-I)**: ITGB2 유전자 돌연변이로 인한 희귀 자가면역 결합면역부전. 2세 이전 75% 사망률, 40세 50% 사망률. **기존 치료 한계**: 항생제·호중구 수혈·조혈줄기세포 이식(공여자 문제, graft-versus-host disease). **Kresladi**: HLA 일치 형제 기증자 없는 LAD-I 소아 환자용 유전자 치료제. **작용 기전**: 환자 자신의 조혈줄기세포 유전자 편집 → ITGB2 발현 회복. **2026년 3월 26일 승인**. 핵심: Kresladi FDA 승인(2026년 3월)으로 FDA 플랫폼 규제가 구체적 제품으로 이행 — Embedding Consolidating.

**FDA Gene Therapy 38개 승인 Comprehensive Review: 플랫폼 규제 체계化[11]**
C. Oo et al.(J Clinical Pharmacology 2026)의 연구는 FDA gene therapy approvals를 통합 분석한다[11]. **핵심 성과 1 — Platform-aligned risk-based approach**: FDA의 플랫폼 위험 기반 접근법. **핵심 성과 2 — Plausible mechanism framework**: 개별화 치료를 위한 메커니즘 프레임워크. **핵심 성과 3 — CMC flexibility initiative**: 화학제조관리 유연성. **핵심 성과 4 — Advanced manufacturing technologies program**: 고급 제조 기술 프로그램. **핵심 성과 5 — AI/ML analytics 적용 확대**: dose selection·safety evaluation·durability prediction. **핵심 성과 6 — Individualized, mechanistically targeted, potentially curative products 지원**. 핵심: FDA gene therapy 플랫폼 규제 체계化 — AI/ML analytics 통합 — FDA/규제 Embedding Consolidating.

**FDA CGT 38개 승인 Assessment: Orphan·Expedited Pathway·Surrogate Endpoints 현황[12]**
Mahnum Shahzad et al.(Clinical Pharmacology and Therapeutics 2026)의 연구는 FDA CGT 승인을 추가 분석한다[12]. **핵심 성과 1 — 86.8% orphan designation**: 희귀질환 대상. **핵심 성과 2 — 92.1% expedited pathway 사용**: 신속 심사 활용. **핵심 성과 3 — 44.7% surrogate endpoints exclusively 의존**: 대리 종점 활용. **핵심 성과 4 — Limited premarket data**: 승인 전 제한적 데이터. **핵심 성과 5 — Postmarketing studies infrequently assess clinical efficacy**: 승인 후 임상 효능 평가 부족. 핵심: FDA CGT 승인 현황 체계적 분석 — FDA/규제 Embedding Consolidating.

**9월 28일 Institutionalizing(Oo FDA 38개 플랫폼 규제) vs 오늘의差别점**: 9/28이 Oo J Clinical Pharmacology으로 **FDA 38개 승인 플랫폼 규제 체계化**를 제시했다면, 오늘은 **Sheikh Annals**으로 **Kresladi FDA 승인(2026년 3월 26일)이라는 구체적 제품**을(制度化→실제 제품 이행), **Shahzad Clinical Pharmacology**으로 **orphan 86.8%·expedited 92.1%·surrogate 44.7% 수치**를(현주소) 동시에 제시한다. Institutionalizing(9/28) → 구체적 제품 승인 + 현황 수치 Embedding(9/29).

실무 함의: 규제 기획팀에서 Sheikh et al.의 Kresladi 승인 사례를 분석하여 플랫폼 규제 기반 제품 개발 전략을 수립해야 한다.

*출처: [Sheikh Kresladi LAD-I FDA Approval Annals of Medicine and Surgery 2026](https://consensus.app/papers/details/f2f27f7392e05d9693a11da0cb87b29d/), [Oo FDA Gene Therapy Approvals J Clinical Pharmacology 2026](https://consensus.app/papers/details/181658e93c825ea581a0664845a98d12/), [Shahzad FDA CGT Assessment Clinical Pharmacology 2026](https://consensus.app/papers/details/24705d5037e85bc9b9863f1aabca040/)*

*#FDA #GeneTherapy #Kresladi #Sheikh #AnnalsOfMedicine #LADI #ITGB2 #March2026Approval #Oo #JClinicalPharmacology #PlatformAligned #RiskBased #PlausibleMechanism #CMC #Manufacturing #AI #ML #Analytics #Shahzad #ClinicalPharmacology #OrphanDesignation #ExpeditedPathway #SurrogateEndpoints #EmbeddingDay #ProductApproval #PlatformRegulation #IndividualizedTherapy #BiomedicalAI #DailyReport*

---

### Post 7: Spatial Transcriptomics — IBD Atlas Clinical Implementation + DBiTplus Multi-Modal: Embedding

🗺️ **[Spatial Transcriptomics] Li et al.로 IBD(ulcerative colitis·Crohn's disease) spatial atlas — 100+ 조직 sections 3M+ cells + CosMx vs Xenium benchmark + multi-center operational feasibility (Nature Communications 2026) + Enninful et al.로 DBiTplus multimodal spatial omics — imaging-based + sequencing-based 통합 + same tissue section에서 RNA + protein 동시 분석 + lymphoma 적용(Nature Methods 2026) + Gao et al.로 gastric cancer spatial atlas — Lymphocyte Aggregated Region + TLS + PD1+CD8 T proximity (Nature Communications 2026): spatial transcriptomics Embedding(안착) 동시 확인**

Spatial transcriptomics의**임상 적용 implementation + multimodal integration실용화(Embedding)**가 출처에서 동시에 확인된다[13][14].

**IBD Spatial Atlas: CosMx vs Xenium Benchmark + Multi-Center Operational Feasibility[13]**
Yi-Ming Li et al.(Nature Communications 2026)의 연구는 IBD(inflammatory bowel disease) spatial atlas를 구축한다[13]. **핵심 성과 1 — 100+ intestinal tissue sections**: non-diseased controls + ulcerative colitis + Crohn's disease. **핵심 성과 2 — 3M+ cells 포함 atlas**: 대규모 공간적 데이터. **핵심 성과 3 — CosMx vs Xenium benchmark**: 두 플랫폼 직접 비교. **핵심 성과 4 — CosMx higher detection efficiency**: UC와 Crohn's disease 모두에서 Xenium 대비 높은 효율. **핵심 성과 5 — Xenium reduced performance**: tissue type·block quality·panel size에 따른 성능 저하. **핵심 성과 6 — CosMx regulatory T cell biology**: UC와 Crohn's disease 모두에서 검증. **핵심 성과 7 — Multi-center operational feasibility**: fixation time·sectioning procedures variation에서도 CosMx 데이터 품질 안정적. 핵심: IBD spatial atlas + CosMx vs Xenium benchmark + multi-center feasibility — spatial transcriptomics Embedding Consolidating.

**DBiTplus Multi-Modal Spatial Omics: Imaging + Sequencing Integration[14]**
Archibald Enninful et al.(Nature Methods 2026)의 연구는 DBiTplus multimodal spatial omics approach를 제시한다[14]. **핵심 성과 1 — Imaging-based + sequencing-based 통합**: 같은 조직 절편에서 RNA + protein 동시 분석. **핵심 성과 2 — DBiTplus 방법**: Deterministic Barcoding in Tissue sequencing plus. **핵심 성과 3 — Spatial barcoding + RNase H-mediated cDNA retrieval**: 조직 아키텍처 보존. **핵심 성과 4 — Imaging-guided deconvolution**: 단일세포 분해능 공간 전사체 atlas 생성. **핵심 성과 5 — Diverse samples 적용**: frozen mouse embryos, FFPE human lymph nodes, lymphoma tissues. **핵심 성과 6 — Lymphomagenesis·progression·transformation mechanism 발견**: lymphoma 연구에서의 적용 확인. 핵심: DBiTplus로 imaging + sequencing multimodal integration 실현 — spatial omics Embedding Consolidating.

**9월 28일 Institutionalizing(Zhang CosMx SCLC vascular-immune + Li pan-cancer 56 LCPs) vs 오늘의差别점**: 9/28이 Zhang Cell Reports Medicine으로 **CosMx SCLC 75 patients 600K cells**을, Li AJHG로 **pan-cancer 56 LCPs macrophage niche**을 제시했다면, 오늘은 **Li Nature Communications**으로 **IBD spatial atlas 3M+ cells + CosMx vs Xenium benchmark + multi-center feasibility**를(IBD 임상 적용安착), **Enninful Nature Methods**으로 **DBiTplus imaging + sequencing multimodal integration**을(multi-modal Embedding), **Gao Nature Communications**으로 **gastric cancer LAR + TLS spatial architecture**를(기존 내용이지만 오늘과 연계) 동시에 제시한다. Institutionalizing(9/28) → IBD 임상 적용 + multimodal integration Embedding(9/29).

실무 함의: spatial transcriptomics 연구팀에서 Li et al.의 CosMx vs Xenium benchmark 결과를 참조하여 플랫폼 선택 기준을 수립해야 한다.

*출처: [Li IBD Spatial Atlas Nature Communications 2026](https://consensus.app/papers/details/02da1d5a4d605f7bb65ef940bb94ed56/), [Enninful DBiTplus Multimodal Nature Methods 2026](https://consensus.app/papers/details/3606420dfdb3555683526ac6b0b8fa3c/), [Gao Gastric Cancer Spatial Nature Communications 2026](https://consensus.app/papers/details/46f3d71acd2e5b6e8812d6886aa485d9/)*

*#SpatialTranscriptomics #Li #IBD #Crohn #UlcerativeColitis #NatureCommunications #CosMx #Xenium #Benchmark #3MillionCells #MultiCenter #Feasibility #Enninful #DBiTplus #NatureMethods #Multimodal #Imaging #Sequencing #Protein #Lymphoma #FFPE #Gao #GastricCancer #LAR #TLS #PD1 #CD8 #EmbeddingDay #ClinicalImplementation #Atlas #OperationalFeasibility #BiomedicalAI #DailyReport*

---

### Post 8: 오늘의 요약 — Embedding(안착 Day) 핵심 정리

🧬 **오늘 6개 영역 핵심 요약:**

9/29(Embedding)의 핵심: Institutionalizing(9/28)된 기술들이 **구체적 제품·치료·적용 사례와 표준화로 안착하며, framework adoption에서 practical deployment로 이행하는 날**이었다.

**1. Kresladi FDA 승인(2026년 3월 26일) — LAD-I Gene Therapy 제품화(Sheikh Annals of Medicine and Surgery 2026)**: ITGB2 유전자 편집으로 HLA 일치 기증자 없는 LAD-I 소아 환자 치료 — FDA 플랫폼 규제가 구체적 제품으로 이행. [Sheikh Annals of Medicine and Surgery 2026]

**2. Nanomaterial-Mediated CRISPR Delivery 산업 표준화(Wang Frontiers Bioengineering 2026)**: LNPs·polymeric·inorganic·EV-derived systems comprehensive review + repeated targeted applications 가능성 — 전달 기술의 산업 표준化安착. [Wang Frontiers Bioengineering 2026]

**3. Precision Oncology AI — TNIK Inhibitor Phase IIa Efficacy(Yoo BJC Reports 2026)**: AI로 설계된 TNIK inhibitor가 IPF 환자에서 Phase IIa efficacy 확인 — AI drug discovery oncology實際 적용. [Yoo BJC Reports 2026]

**4. AlphaFold Practical Applications Comprehensive Review(Yin Frontiers Molecular Biosciences 2026)**: AF→AF2→AF3 architectural evolution + drug discovery·enzyme engineering·disease research 적용 체계화 — 실용적 적용安착. [Yin Frontiers Molecular Biosciences 2026]

**5. Single-Cell FM Scaling Law 부재確認(DenAdel Nature Methods 2026)**: 22.2M cells 400 models 6,400 experiments에서 scaling law 부재 + plateau 확인 — foundation model의 데이터 크기보다 균형 중요. [DenAdel Nature Methods 2026]

**6. IBD Spatial Atlas + CosMx vs Xenium Benchmark(Li Nature Communications 2026)**: 100+ sections 3M+ cells + CosMx higher efficiency + multi-center operational feasibility — spatial transcriptomics의 임상 적용安착. [Li Nature Communications 2026]

**9월 30일 전망**: Embedding된 기술들의 구체적 제품·치료 적용 속도와 표준화采纳가 핵심 변수. 특히 Kresladi 이후 LAD-I 치료제의 실제 환자 적용, IBD spatial atlas의 multi-center 임상 trials 통합, AlphaFold practical applications의 drug discovery pipeline 구체적 적용이 관전.

*출처: [Sheikh Kresladi LAD-I Annals of Medicine and Surgery 2026](https://consensus.app/papers/details/f2f27f7392e05d9693a11da0cb87b29d/), [Wang Nanomaterial CRISPR Frontiers Bioengineering 2026](https://consensus.app/papers/details/f43692af0ccb54b684ef6714b3de8d82/), [Zhao DNA RNA Editing Molecular Biomedicine 2026](https://consensus.app/papers/details/ab669ea6603759258fd73951324f50a5/), [Yoo Precision Oncology BJC Reports 2026](https://consensus.app/papers/details/3061bab99a9351b297c698ef342d7f34/), [Mao AI Drug Discovery Frontiers Pharmacology 2026](https://consensus.app/papers/details/ca5321af0bb656e095b6108766231764/), [Yin AlphaFold Frontiers Molecular Biosciences 2026](https://consensus.app/papers/details/880e72fce35255c4887811c76849c03a/), [Feldman AlphaFold Adversarial Computational Biotechnology 2026](https://consensus.app/papers/details/68f35194db525fb68a7bc8c10546001b/), [DenAdel Single-Cell FM Nature Methods 2026](https://consensus.app/papers/details/f0f6bddc16985563ad8478918950e0f4/), [Ji CAPTAIN Multimodal Nature Communications 2026](https://consensus.app/papers/details/40361e55d4815c1dae3d5f6a95d4468a/), [Wang CellVQ Nature Communications 2026](https://consensus.app/papers/details/89622623baa35922aaca1c5b88e6ce8b/), [Oo FDA Gene Therapy J Clinical Pharmacology 2026](https://consensus.app/papers/details/181658e93c825ea581a0664845a98d12/), [Shahzad FDA CGT Clinical Pharmacology 2026](https://consensus.app/papers/details/24705d5037e85bc9b9863f1aabca040/), [Li IBD Spatial Atlas Nature Communications 2026](https://consensus.app/papers/details/02da1d5a4d605f7bb65ef940bb94ed56/), [Enninful DBiTplus Nature Methods 2026](https://consensus.app/papers/details/3606420dfdb3555683526ac6b0b8fa3c/)*

*#EmbeddingDay #Summary #Sheikh #Kresladi #LADI #ITGB2 #March2026 #Wang #Nanomaterial #CRISPRDelivery #LipidNanoparticle #Yoo #PrecisionOncology #TNIK #PhaseIIa #Yin #AlphaFold #FrontiersMolecularBiosciences #Feldman #AlphaFold3 #Adversarial #DenAdel #ScalingLaw #Plateau #Ji #CAPTAIN #Multimodal #Wang #CellVQ #SCD #Oo #FDA #PlatformAligned #Shahzad #Orphan #ExpeditedPathway #Li #IBD #CosMx #Xenium #Enninful #DBiTplus #Multimodal #Embedding #Institutionalizing #ProductLaunch #ClinicalDeployment #Atlas #BiomedicalAI #DailyReport*

---

## Sources

[1] [Sheikh et al. — Gene therapy for leukocyte adhesion deficiency type I: FDA approval, clinical evidence, and future perspectives. Annals of Medicine and Surgery 2026](https://consensus.app/papers/details/f2f27f7392e05d9693a11da0cb87b29d/)
[2] [Wang et al. — Advances in nanomaterial-mediated CRISPR/Cas delivery: from lipid nanoparticles to vesicle-derived systems. Frontiers in Bioengineering and Biotechnology 2026](https://consensus.app/papers/details/f43692af0ccb54b684ef6714b3de8d82/)
[3] [Zhao et al. — DNA and RNA editing for the therapy of human diseases: current status, challenges, and future prospects. Molecular Biomedicine 2026](https://consensus.app/papers/details/ab669ea6603759258fd73951324f50a5/)
[4] [Yoo et al. — Precision oncology in the age of AI: lessons from AI-driven drug discovery and clinical translation. BJC Reports 2026](https://consensus.app/papers/details/3061bab99a9351b297c698ef342d7f34/)
[5] [Mao et al. — Artificial intelligence in drug discovery: from algorithmic foundations to clinical translation. Frontiers in Pharmacology 2026](https://consensus.app/papers/details/ca5321af0bb656e095b6108766231764/)
[6] [Yin et al. — Protein structure prediction powered by artificial intelligence: from biochemical foundations to practical applications. Frontiers in Molecular Biosciences 2026](https://consensus.app/papers/details/880e72fce35255c4887811c76849c03a/)
[7] [Feldman et al. — Adversarial Sequence Mutations in AlphaFold and ESMFold Reveal Nonphysical Structural Invariance, Confidence Failures, and Concerns for Protein Design. Computational and Structural Biotechnology Journal 2026](https://consensus.app/papers/details/68f35194db525fb68a7bc8c10546001b/)
[8] [DenAdel et al. — Evaluating the role of pre-training dataset size and diversity on single-cell foundation model performance. Nature Methods 2026](https://consensus.app/papers/details/f0f6bddc16985563ad8478918950e0f4/)
[9] [Ji et al. — CAPTAIN: a multimodal foundation model pretrained on co-assayed single-cell RNA and protein. Nature Communications 2026](https://consensus.app/papers/details/40361e55d4815c1dae3d5f6a95d4468a/)
[10] [Wang et al. — Illuminating cell states by a comprehensive and interpretable single cell foundation model. Nature Communications 2026](https://consensus.app/papers/details/89622623baa35922aaca1c5b88e6ce8b/)
[11] [Oo et al. — FDA Gene Therapy Approvals (1998–2025): Current Status, Regulatory Evolution, and Future Directions. J Clinical Pharmacology 2026](https://consensus.app/papers/details/181658e93c825ea581a0664845a98d12/)
[12] [Shahzad et al. — Assessment of United States Food and Drug Administration Approval of Cell and Gene Therapies. Clinical Pharmacology & Therapeutics 2026](https://consensus.app/papers/details/24705d5037e85bc9b9863f1aabca040/)
[13] [Li et al. — Spatial transcriptomics atlas of inflammatory bowel disease to guide implementation in research consortiums and clinical trials. Nature Communications 2026](https://consensus.app/papers/details/02da1d5a4d605f7bb65ef940bb94ed56/)
[14] [Enninful et al. — Integration of imaging-based and sequencing-based spatial omics mapping on the same tissue section via DBiTplus. Nature Methods 2026](https://consensus.app/papers/details/3606420dfdb3555683526ac6b0b8fa3c/)
[15] [Gao et al. — Spatial transcriptomics of gastric cancer reveals lymphocyte aggregated regions and tertiary lymphoid structures. Nature Communications 2026](https://consensus.app/papers/details/46f3d71acd2e5b6e8812d6886aa485d9/)